Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O- deethylation in human liver microsomes

Drug Metabolism and Disposition

Volumn 27, Issue 8, 1999, Pages 860-865

  Kobayashi, Kaoru ^a   Nakajima, Miki ^b   Oshima, Kanako ^a   Shimada, Noriaki ^c   Yokoi, Tsuyoshi ^b   Chiba, Kan ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c DAIICHI PURE CHEMICALS CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE; DIMETHYLNITROSAMINE DEMETHYLASE; FLUVOXAMINE; PHENACETIN;

ARTICLE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME BINDING; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

ANALGESICS, NON-NARCOTIC; ANILINE COMPOUNDS; BACULOVIRIDAE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2E1; DEALKYLATION; FLUVOXAMINE; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; PHENACETIN; RECOMBINANT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032793678     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bartoli A, Xiaodong S, Gatti G, Cipolla G, Marchiselli R and Perucca E (1996) The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: A comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monit 18:586-591.
2. Boobis AR, Kahn GC, Whyte C, Brodie MJ and Davies DS (1981) Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. Biochem Pharmacol 30:2451-2456.
3. PA (P450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696-7700.
4. Gillam EM and Reilly PB (1988) Phenacetin O-deethylation by human liver microsomes: Kinetics and propranolol inhibition. Xenobiotica 18:95-104.
5. Guengerich FP, Müller-Enoch D and Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287-295.
6. Kahn GC, Boobis AR, Brodie MJ, Toverud EL, Murray S and Davies DS (1985) Phenacetin O-deethylase: An activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? Br J Clin Pharmacol 20:67-76.
7. Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T and Kuroiwa Y (1998) Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br J Clin Pharmacol 45:361-368.
8. Küpfer A and Preisig R (1984) Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26:753-759.
9. Morgan ET, Koop DR and Coon MJ (1982) Catalytic activity of cytochrome P-450 isozyme 3a isolated from liver microsomes of ethanol-treated rabbits. Oxidation of alcohols. J Biol Chem 257:13951-13957.
10. Murray BP, Edwards RJ, Murray S, Singleton AM, Davies DS and Boobis AR (1993) Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic activation of PhIP, Carcinogenesis 14:585-592.
11. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF and Kamataki T (1994) Phenotyping of CYP1A2 in Japanese population analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomark Prev 3:413-421.
12. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW (1996) P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
13. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
14. Parkinson A (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pharmacol 24:45-57.
15. Pastrakuljic A, Tang BK, Roberts EA and Kalow W (1997) Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 53: 531-538.
16. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
17. Sesardic D, Boobis AR, Edwards RJ and Davies DS (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26:363-372.
18. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
19. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
20. Xiaodong S, Gatti G, Bartoli A, Cipolla G, Crema F and Perucca E (1994) Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers. Ther Drug Monit 16:248-250.
21. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.